The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination

Journal of Pathology

Volumn 227, Issue 2, 2012, Pages 234-244

  Balz, Lydia M ^a   Bartkowiak, Kai ^b   Andreas, Antje ^b   Pantel, Klaus ^b   Niggemann, Bernd ^a   Zänker, Kurt S ^a   Brandt, Burkhard H ^b,c   Dittmar, Thomas ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

cell migration; disseminated tumour cells; EGFR; HER2; HER3; PI3K AKT signalling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STAINING; TREATMENT FAILURE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84860668033     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3991     Document Type: Article

References (35)

1. DiGiovanna MP, Stern DF, Edgerton SM, et al., Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23: 1152-1160.
2. Eccles SA,. Cell biology of lymphatic metastasis. The potential role of c-erbB oncogene signalling. Recent Results Cancer Res 2000; 157: 41-54.
3. Eccles SA,. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 393-406.
4. Thor AD, Edgerton SM, Liu S, et al., Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001; 7: 2415-2424.
5. Kruser TJ, Wheeler DL,. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010; 316: 1083-1100.
6. Sergina NV, Rausch M, Wang D, et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
7. Hsieh AC, Moasser MM,. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007; 97: 453-457.
8. Sassen A, Rochon J, Wild P, et al., Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008; 10: R2.
9. Holbro T, Beerli RR, Maurer F, et al., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100: 8933-8938.
10. Xue C, Liang F, Mahmood R, et al., ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 2006; 66: 1418-1426.
11. Smirnova T, Zhou ZN, Flinn RJ, et al., Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 2011; 9: 706-715.
12. Manning BD, Cantley LC,. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274.
13. Huang J, Manning BD,. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217-222.
14. Falasca M, Logan SK, Lehto VP, et al., Activation of phospholipase Cγ by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J 1998; 17: 414-422.
15. Piccolo E, Innominato PF, Mariggio MA, et al., The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration. Oncogene 2002; 21: 6520-6529.
16. Dittmar T, Husemann A, Schewe Y, et al., Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 2002; 16: 1823-1825.
17. Braun S, Pantel K, Muller P, et al., Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
18. Braun S, Vogl FD, Naume B, et al., A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
19. Schardt JA, Meyer M, Hartmann CH, et al., Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005; 8: 227-239.
20. Pantel K, Schlimok G, Braun S, et al., Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
21. Muller V, Alix-Panabieres C, Pantel K,. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 2010; 46: 1189-1197.
22. Ignatiadis M, Rothe F, Chaboteaux C, et al., HER2-positive circulating tumor cells in breast cancer. PLoS One 2011; 6: e15624.
23. Nguyen DX, Bos PD, Massague J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
24. Pantel K, Alix-Panabieres C, Riethdorf S,. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-351.
25. Wulfing P, Borchard J, Buerger H, et al., HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12: 1715-1720.
26. Brandt BH, Roetger A, Dittmar T, et al., c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999; 13: 1939-1949.
27. Bartkowiak K, Effenberger KE, Harder S, et al., Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res 2010; 9: 3158-3168.
28. Helms MW, Kemming D, Contag CH, et al., TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Cancer Res 2009; 69: 5049-5056.
29. Heyder C, Gloria-Maercker E, Hatzmann W, et al., Role of the β1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metast 2005; 22: 99-106.
30. 2+ flux measurement on isolated human B cells that uses flow cytometry. Clin Diagn Lab Immunol 1997; 4: 70-74.
31. Katterle Y, Brandt BH, Dowdy SF, et al., Antitumour effects of PLC-γ1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Br J Cancer 2004; 90: 230-235.
32. Lee-Hoeflich ST, Crocker L, Yao E, et al., A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-5887.
33. Muraoka-Cook RS, Garrett J, Sanchez VK, et al., ErbB3 ablation impairs phosphatidylinositol 3-kinase (PI3K)/AKT-dependent mammary tumorigenesis. Cancer Res 2011; 71: 3941-3951.
34. Junttila TT, Akita RW, Parsons K, et al., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440.
35. Schoeberl B, Faber AC, Li D, et al., An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70: 2485-2494.